Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29542551 | 0.74 | ALDH1A1 (0.39) | ALDH1A1MAPTALOX12POLBTSHR | |
| SCHEMBL30444641 | 0.73 | ALDH1A1 (0.38) | ALDH1A1HPGDHSD17B10MAPTPKM | |
| SCHEMBL25464698 | 0.73 | ALDH1A1 (0.38) | ALDH1A1HPGDHSD17B10MAPTPKM | |
| SCHEMBL29543015 | 0.72 | ALDH1A1 (0.40) | ALDH1A1HPGDMAPTPKMKMT2A | |
| SCHEMBL29542701 | 0.71 | KDM4E (0.40) | ALDH1A1KMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL29542457 | 0.71 | ALDH1A1 (0.39) | ALDH1A1HPGDHSD17B10MAPTPOLB | |
| SCHEMBL17033019 | 0.71 | ALDH1A1 (0.42) | ALDH1A1HPGDPOLBCASP3CYP1A2 | |
| SCHEMBL6659478 | 0.68 | ALDH1A1 (0.49) | ALDH1A1HPGDHSD17B10MAPTPKM | |
| SCHEMBL22813353 | 0.68 | ALDH1A1 (0.42) | ALDH1A1HPGDHSD17B10MAPTPOLB | |
| SCHEMBL6662082 | 0.68 | ALDH1A1 (0.45) | ALDH1A1HPGDHSD17B10MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| US-20230265090-A1 | QUINAZOLINE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230265090-A1 | QUINAZOLINE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-08-24 | — | — | US | disclosed |
| EP-4219493-A1 | BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2023-08-02 | — | — | EP | disclosed |
| EP-4186903-A1 | QUINAZOLINE COMPOUND | Medshine Discovery Inc. (CN) | 2023-05-31 | — | — | EP | disclosed |
| EP-3728254-B1 | BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-02-15 | — | — | EP | disclosed |
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-01-14 | — | — | US | disclosed |
| WO-2020254451-A1 | ANTICANCER COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-24 | — | — | WO | disclosed |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
| EP-3286172-B1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-9670487-B2 | Cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670487-B2 | Cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670487-B2 | Cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20130053572-A1 | Novel Cationic Lipids for Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-02-28 | — | — | US | disclosed |
| US-20130053572-A1 | Novel Cationic Lipids for Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-02-28 | — | — | US | disclosed |
| US-20130053572-A1 | Novel Cationic Lipids for Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-02-28 | — | — | US | disclosed |
| WO-2011090965-A1 | NOVEL CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011090965-A1 | NOVEL CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265090-A1 | QUINAZOLINE COMPOUND | ABCG2, CYP3A7, ABL1 | ALDH1A1 2369/4885HPGD 1826/4885HSD17B10 2605/4885 |
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | ALDH1A1 1453/4885HPGD 3837/4885HSD17B10 4557/4885 |
| US-20130053572-A1 | Novel Cationic Lipids for Oligonucleotide Delivery | NPC1L1, CETP, LIPA | ALDH1A1 1441/4885HPGD 4218/4885HSD17B10 415/4885 |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | ALDH1A1 1272/4885HPGD 3877/4885HSD17B10 4542/4885 |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | ALDH1A1 1511/4885HPGD 3813/4885HSD17B10 4598/4885 |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | ALDH1A1 1301/4885HPGD 3835/4885HSD17B10 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.